Zetia Labeling Adds Myopathy/Rhabdomyolysis Precaution
This article was originally published in The Pink Sheet Daily
Executive Summary
Revised labeling for Merck's lipid-lowering therapy notes most cases of rhabdomyolysis occurred in patients who had been taking statins. The skeletal muscle precaution follows the recent addition of a precaution against use with cyclosporine.
You may also be interested in...
Vytorin, Zetia Labeling Adds Precaution On Cyclosporine Coadministration
Revised labeling for the Merck/Schering-Plough products recommends caution when coadministering ezetimibe and cyclosporine. In healthy patients, coadministration of cyclosporine and ezetimibe was associated with a 15% increase in cyclosporine AUC, labeling states.
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).
No More NASHing Of Teeth: Madrigal’s Resmetirom Approval Ends Years Of Industry Frustration
US FDA clears first MASH (formerly NASH) therapy, nearly four years after one had been initially anticipated. With the accelerated approval path established, Madrigal gets the opportunity to create a marketplace with Rezdiffra (resmetirom), and candidates in the pipeline get a clear target.